Drugs / FGF401
FGF401
also known as
CPD84 · N-{5-CYANO-4-[(2-METHOXYETHYL)AMINO]PYRIDIN-2-YL}-7-FORMYL-6-[(4-METHYL-2-OXOPIPERAZIN-1-YL)METHYL]-1,2,3,4-TETRAHYDRO-1,8-NAPHTHYRIDINE-1-CARBOXAMIDE · ROBLITINIB · ROBLITINIB (FGF401)
Small molecule targets FGFR4 via inhibition
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/2 | NCT02325739 | Dec 2014 → May 2019 | hepatocellular carcinoma | Novartis Pharmaceuticals | Completed | No outcome recorded |
Evidence & citations 9 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | FGF401 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT02325739 ↗ |
| Known as | CPD84 | ChEMBL registry synonym — accepted as the source's own label CHEMBL3908979 ↗ |
| Known as | N-{5-CYANO-4-[(2-METHOXYETHYL)AMINO]PYRIDIN-2-YL}-7-FORMYL-6-[(4-METHYL-2-OXOPIPERAZIN-1-YL)METHYL]-1,2,3,4-TETRAHYDRO-1,8-NAPHTHYRIDINE-1-CARBOXAMIDE | ChEMBL registry synonym — accepted as the source's own label CHEMBL3908979 ↗ |
| Known as | ROBLITINIB | ChEMBL registry synonym — accepted as the source's own label CHEMBL3908979 ↗ |
| Known as | ROBLITINIB (FGF401) | ChEMBL registry synonym — accepted as the source's own label CHEMBL3908979 ↗ |
| Action | Inhibit | “FGF401 is a FGFR4 inhibitor.” NCT02325739 ↗ |
| Modality | Small molecule | — CHEMBL3908979 ↗ |
| Route | Oral | “Oral FGF401 was administered on a continuous once daily (QD) dosing regimen for both FGF401 single agent and in combination with PDR001 parts.” NCT02325739 ↗ |
| Target | FGFR4 | “FGF401 is a FGFR4 inhibitor.” NCT02325739 ↗ |